Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Gross Profit (2022 - 2025)

Axsome Therapeutics' Gross Profit history spans 4 years, with the latest figure at $183.7 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 69.67% year-over-year to $183.7 million; the TTM value through Dec 2025 reached $591.0 million, up 67.72%, while the annual FY2025 figure was $591.0 million, 67.72% up from the prior year.
  • Gross Profit for Q4 2025 was $183.7 million at Axsome Therapeutics, up from $159.1 million in the prior quarter.
  • Across five years, Gross Profit topped out at $183.7 million in Q4 2025 and bottomed at $7.8 million in Q2 2022.
  • The 4-year median for Gross Profit is $83.1 million (2023), against an average of $87.0 million.
  • The largest annual shift saw Gross Profit skyrocketed 437.21% in 2023 before it fell 21.05% in 2024.
  • A 4-year view of Gross Profit shows it stood at $22.1 million in 2022, then surged by 190.55% to $64.2 million in 2023, then skyrocketed by 68.74% to $108.3 million in 2024, then surged by 69.67% to $183.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Gross Profit are $183.7 million (Q4 2025), $159.1 million (Q3 2025), and $136.6 million (Q2 2025).